482 related articles for article (PubMed ID: 27861902)
1. The molecular basis of breast cancer pathological phenotypes.
Heng YJ; Lester SC; Tse GM; Factor RE; Allison KH; Collins LC; Chen YY; Jensen KC; Johnson NB; Jeong JC; Punjabi R; Shin SJ; Singh K; Krings G; Eberhard DA; Tan PH; Korski K; Waldman FM; Gutman DA; Sanders M; Reis-Filho JS; Flanagan SR; Gendoo DM; Chen GM; Haibe-Kains B; Ciriello G; Hoadley KA; Perou CM; Beck AH
J Pathol; 2017 Feb; 241(3):375-391. PubMed ID: 27861902
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract][Full Text] [Related]
3. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
Kurozumi S; Joseph C; Sonbul S; Aleskandarany MA; Pigera M; Alsaleem M; Alsaeed S; Kariri Y; Nolan CC; Diez-Rodriguez M; Johnston S; Mongan NP; Fujii T; Shirabe K; Martin SG; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2018 Nov; 172(1):61-68. PubMed ID: 30056565
[TBL] [Abstract][Full Text] [Related]
6. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
7. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
8. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
[TBL] [Abstract][Full Text] [Related]
9. Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics.
McCart Reed AE; Kutasovic JR; Lakhani SR; Simpson PT
Breast Cancer Res; 2015 Jan; 17(1):12. PubMed ID: 25849106
[TBL] [Abstract][Full Text] [Related]
10. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
Wolf B; Goebel G; Hackl H; Fiegl H
BMC Cancer; 2016 Oct; 16(1):821. PubMed ID: 27770790
[TBL] [Abstract][Full Text] [Related]
11. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer.
Arora A; Abdel-Fatah TM; Agarwal D; Doherty R; Moseley PM; Aleskandarany MA; Green AR; Ball G; Alshareeda AT; Rakha EA; Chan SY; Ellis IO; Madhusudan S
Mol Cancer Ther; 2015 Apr; 14(4):1057-65. PubMed ID: 25673821
[TBL] [Abstract][Full Text] [Related]
13. PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective.
Cooper LA; Demicco EG; Saltz JH; Powell RT; Rao A; Lazar AJ
J Pathol; 2018 Apr; 244(5):512-524. PubMed ID: 29288495
[TBL] [Abstract][Full Text] [Related]
14. Genes and functions from breast cancer signatures.
Huang S; Murphy L; Xu W
BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
[TBL] [Abstract][Full Text] [Related]
15. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
16. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
[TBL] [Abstract][Full Text] [Related]
17. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
[TBL] [Abstract][Full Text] [Related]
18. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
20. Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.
Kim D; Li R; Dudek SM; Ritchie MD
J Biomed Inform; 2015 Aug; 56():220-8. PubMed ID: 26048077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]